GeoVax Labs, Inc. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016; filed March 24, 2017. GeoVax is a clinical-stage vaccine developer using its MVA-VLP platform. Its preventive HIV vaccine is in human trials; other programs, including Zika, hemorrhagic fever viruses, malaria, hepatitis B and cancer, are primarily preclinical. The company had no product sales.
Financial results and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Grant revenue | $828,918 | $428,081 |
| Research and development expense | $1,970,859 | $1,693,102 |
| General and administrative expense | $2,131,426 | $1,429,731 |
| Operating loss | $3,273,367 | $2,694,752 |
| Net loss | $3,271,701 | $2,689,287 |
| Net loss per share | $0.08 | $0.08 |
| Cash used in operating activities | $1,946,119 | $2,705,263 |
Grant revenue is government funding recognized as related costs are incurred, not product revenue. Operating expenses exceeded grant revenue by approximately $3.27 million in 2016; conventional profit margins are not meaningful for this pre-revenue company. Research and development expense rose about 16%, while general and administrative expense rose about 49%. The latter included $912,862 of warrant-modification expense; total stock-based compensation was $967,667, versus $67,905 in 2015.
At year-end, cash and cash equivalents were $454,030 (down from $1,060,348), working capital was $174,532 (down from $1,109,985), total assets were $610,217, and stockholders’ equity was $240,370. Current liabilities were $369,847. The filing reports no long-term debt or committed credit lines. Cash fell by $606,318 during the year; financing provided $1,339,801, chiefly from warrant exercises. Outstanding obligations included approximately $152,000 of lease payments and $305,000 of purchase commitments, both due within one year.
The auditor’s report and management identify substantial doubt about GeoVax’s ability to continue as a going concern. Management expected available cash and government support to fund planned operations only into the second quarter of 2017. Approximately $505,487 in grant funds remained available for 2017, but additional capital was required. Cash-flow comparison is affected by timing of grant-funded activity and financing; the 2016 operating cash outflow was lower than 2015 despite the larger reported net loss.
Programs, outlook and material risks
- HIV: The preventive clade B program had completed Phase 1 and Phase 2a testing in approximately 500 participants and was described as well tolerated. HVTN 114 began in January 2017 to test late boosts; NIAID funds the trial directly through HVTN. GeoVax received a staged development contract with a $199,442 base award and up to $7.6 million in options. The company also reported NIAID SBIR support.
- Other pipeline: GeoVax reported 100% protection in animal studies for single-dose Ebola and Zika candidates, but these are preclinical findings, not evidence of human efficacy. In March 2017, it agreed to collaborate with American Gene Technologies on a proposed Phase 1 HIV immunotherapy trial. The company anticipated that preclinical work could support a cancer-vaccine IND within about two years, subject to results.
- Funding and dilution: Management planned to seek grants, clinical-trial support, equity, debt or convertible financing. If financing is unavailable or costly, programs may be delayed, reduced or stopped. During 2016, 21.9 million shares were issued through warrant exercises for $1.34 million. At year-end, 30.7 million warrants were outstanding at $0.05 per share, and Series C preferred stock was convertible into approximately 57.4 million common shares. These securities present substantial potential dilution.
- Development and operating risks: Candidates remain unapproved and require further testing, manufacturing and regulatory review. GeoVax relies on third parties for manufacturing, trials and research, and lacks its own commercial manufacturing, sales and marketing capability. Trial timing, safety or efficacy results, regulatory approval, collaborator support and grant availability are uncertain. Management gave no forward cost or completion estimates because of these uncertainties.
- Other contingencies: The Emory license carries up to approximately $3.45 million in contingent milestone payments, plus royalties upon commercialization; milestones were not included as current contractual obligations because achievement was not considered probable or reasonably estimable. No material legal proceedings or material off-balance-sheet arrangements were reported. Management assessed disclosure controls and internal control over financial reporting as effective at year-end.
Most important facts for investors to verify
- Actual cash runway and subsequent financing, grant receipts, and warrant exercises after March 21, 2017; the filing reports $49,167 from warrant exercises through that date.
- Whether NIAID exercised the anticipated development-contract option and whether remaining grant funding was available on the expected schedule.
- HVTN 114 progress, trial results, and the timing and funding of any later-stage HIV efficacy studies.
- Fully diluted share count and the potential effects of outstanding warrants, options and convertible preferred stock, including applicable adjustment provisions.
- Whether preclinical Ebola and Zika findings translate into human safety and efficacy, and whether the proposed HIV immunotherapy and cancer development plans advance.